(redirected from Ciprofloxacin-Resistant)
CIPRChartered Institute of Public Relations (UK)
CIPRCentre for Integrated Petroleum Research
CIPRCommission Internationale de Protection Radiologique (French: International Commission on Radiological Protection; est. 1928)
CIPRComisión Internacional de Protección Radiológica
CIPRCommission Internationale pour la Protection du Rhin Contre la Pollution (French: International Commission for the Protection of the Rhine against Pollution)
CIPRCenter for Imaging and Pharmaceutical Research
CIPRContractor Insurance/Pension Review
CIPRCenter for Information Processing Research (Renssalaer Polytechnic Institute)
CIPRCommissione Internazionale per la Protezione del Reno dall'Inquinamento (International Commission for the Protection of the Rhine against Pollution)
CIPRCommission Internationale de Protection contre les Radiations Ionisantes (French)
CIPRConcept In Process Review
CIPRCommittee for Investigation on Persecution of Religion in China
CIPRCold In-Place Recycled Pavements (road pavement)
References in periodicals archive ?
A small pilot study of patients attending Homerton University Hospital's urology nurse consultant-led TRUS biopsy clinic was undertaken to ascertain the rate of ciprofloxacin-resistant bacteria in this population.
Ciprofloxacin-Resistant Salmonella enterica Serotype Typhi, United States, 1999-2008.
Inpast, fluoroquinolones showed excellent clinical activity against Enterobacteriaceae including Klebsiella, but the frequency of ciprofloxacin-resistant Klebsiella pneumoniae has increased worldwide in recent years.
Molecular characterization of Neisseria gonorrhoeae identifies transmission and resistance of one ciprofloxacin-resistant strain.
8 percent of patients had ciprofloxacin-resistant E.
The sudden appearance of ciprofloxacin-resistant gonorrhoea in South Africa was first reported among isolates tested in Durban in 2003.
But in the 1990s, the CDC noted the emergence in Asia of ciprofloxacin-resistant gonorrhea.
The purportedly resistant strains have included community-acquired methicillin-resistant Staphylococcus aureus (MRSA) (4,5) and ciprofloxacin-resistant Pseudomonas spp.
Ciprofloxacin plus rifampin may be a third, but less-desirable, vancomycin alternative because ciprofloxacin use may result in increased MRSA rates and because the isolates often test ciprofloxacin-resistant, per the flowchart (Figure 1).
His retrospective case-control study demonstrated that these patient characteristics constitute powerful risk factors that markedly increase the odds of infection by a ciprofloxacin-resistant isolate of Escherichia coli.